Chemo-immunotherapy regimens are now recommended as first-line treatment for patients with advanced esophageal squamous cell carcinoma (ESCC), however survival outcomes remain unsatisfactory. Here the authors report the results of a phase 2 trial of toripalimab (anti-PD1) plus chemotherapy and radiotherapy in patients with treatment-naïve advanced ESCC.
- Lei Wu
- Baisen Li
- Qifeng Wang
